Chronic Hepatitis C Virus (HCV) Infection

Also known as: Chronic Hepatitis C-virus Infection / Hepatitis C Virus Chronic Infection / Chronic Viral Hepatitis C / Hepatitis C, Chronic / Chronic Hepatitis C Viral Infection / Chronic Hepatitis C / Hepatitis C Chronic / Chronic Hepatitis C (CHC) / Chronic Hepatitis C Virus (HCV) / Chronic HCV Hepatitis C / Chronic Hepatitis C Infection / Chronic Hepatitis C Virus Infection / Chronic Hepatitis C (HCV)

DrugDrug NameDrug Description
DB09102DaclatasvirDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Daclatasvir was the first drug with demonstrated safety and therapeutic efficacy in treating HCV genotype 3 without the need for co-administration of interferon or [DB00811]. It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly. Daclatasvir is shown to target both the cis- and trans-acting functions of NS5A and disrupts the function of new HCV replication complexes by modulating the NS5A phosphorylation status [A19640]. The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype 3 patients. According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line therapy. The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. Combination therapies that include daclatasir can be used for challenging-to-treat patients who have HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV [L863]. The therapy is intended to cure or achieve a sustained virologic response (SVR12), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626]. Daclatasvir was FDA-approved in July 2015 for use with [DB08934] (Sovaldi) with or without [DB00811] to treat HCV genotype 1 and 3 infections. The SVR12 in HCV genotype 1a-infected treatment-naïve subjects without and with cirrhosis undergoing daclatasvir and [DB08934] therapy were 88% and 99%, respectively [FDA Label]. The same dosing regimen in treatment-naïve patients with HCV genotype 3 infection with or without cirrhosis achieved SVR12 rates of 71% and 98%, respectively [FDA Label].
DB06210EltrombopagEltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
DB00105Interferon alfa-2bInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2a is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed. In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2a for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2a was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626]. Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with [DB00811] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2a and [DB00811] have been shown to achieve a SVR between 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment.
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed. In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C [A19593]. Peginterferon alfa-2b was used alongside [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [A19626]. Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label]. When combined together, Peginterferon alfa-2b and [Ribavirin] have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.
DB00811RibavirinProducing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. It is reported that ribavirin might be only effective in early stages of viral hemorrhagic fevers including Lasser fever, Crimean-Congo hemorrhagic fever, Venezuelan hemorrhagic fever, and Hantavirus infection. Ribavirin is a prodrug that is metabolized into nucleoside analogs that blocks viral RNA synthesis and viral mRNA capping. Before the development of newer drugs, ribavirin and [DB00008]/[DB00022] dual therapy was considered the first-generation and standard antiviral treatment [A19626]. The dual therapy was administered for 48 weeks in patients with genotype 1, 4, 5, and 6, and 24 weeks in patients with genotype 2 and 3 [A19626]. Newer drugs developed as Hepatitis C viral infection treatments can be used to reduce or eliminate the use of ribavirin, which are associated with serious adverse effects. They also improve therapeutic efficacy in patients with failed [DB00008]/[DB00022] and ribavirin-based therapy. The potential use of ribavirin as a treatment for acute myeloid leukemia is currently under investigation. According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), ribavirin is typically used as an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. Ribavirin is added to decrease relapse rates by accelerating viral clearance early in the treatment course [A19645]. When used to treat Hepatitis C virus (HCV) infections, it is always used as a part of combination therapies as ribavirin monotherapy is not efficacious in the treatment of chronic hepatitis C infection [A19644]. Additionally, including ribavirin in the regimen can increase the risk of anemia. In HCV genotye 1/2/3/4/5/6 patients, ribavirin can be used in combination therapy involving [DB09102] and [DB08934], Eplusa ([DB08934], [DB11613]), Harvoni ([DB08934], [DB09027]), [DB06290] and [DB08934], Viekira Pak ([DB09296], [DB09297], [DB00503], [DB09183]), Technivie ([DB00503], [DB09296], [DB09297]) and Zepatier ([DB11574], [DB11575]). Addition of weight-based ribavirin to Technivie therapy increased sustained virologic response after 12 weeks of daily therapy (SVR12) from 90% to 97% in patients with HCV genotype 1a and 90.9% to 100% in HCV genotype 4 patients [L852]. Zepatier therapy along with ribavirin improved SVR in HCV genotype 5 patients. Combination therapy of ribavirin and [DB00008] results in the SVR of 44% in patients with genotype 1 infection and 70% in patients with genotype 2-6. The inclusion of ribavirin in the combination therapies depend on individual patient's profile, for example if HCV genotype 3 patient has a Y93H genetic variant and compensated cirrhosis.
DrugDrug NameTargetType
DB09102DaclatasvirNonstructural Protein 5A (NS5A)target
DB09102DaclatasvirCytochrome P450 3A5enzyme
DB09102DaclatasvirCytochrome P450 3A4enzyme
DB09102DaclatasvirCytochrome P450 3A43enzyme
DB09102DaclatasvirCytochrome P450 3A7enzyme
DB09102DaclatasvirMultidrug resistance protein 1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B3transporter
DB09102DaclatasvirATP-binding cassette sub-family G member 2transporter
DB06210EltrombopagThrombopoietin receptortarget
DB06210EltrombopagCytochrome P450 2C8enzyme
DB06210EltrombopagCytochrome P450 1A2enzyme
DB06210EltrombopagUDP-glucuronosyltransferase 1-1enzyme
DB06210EltrombopagUDP-glucuronosyltransferase 1-3enzyme
DB06210EltrombopagSolute carrier organic anion transporter family member 1B1transporter
DB06210EltrombopagATP-binding cassette sub-family G member 2transporter
DB06210EltrombopagUDP-glucuronosyltransferase 1-9enzyme
DB00105Interferon alfa-2bInterferon alpha/beta receptor 2target
DB00105Interferon alfa-2bInterferon alpha/beta receptor 1target
DB00105Interferon alfa-2bCytochrome P450 1A2enzyme
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2C9enzyme
DB00811RibavirinRNA-directed RNA polymerase Ltarget
DB00811RibavirinEctonucleotide pyrophosphatase/phosphodiesterase family member 1target
DB00811RibavirinRNA-directed RNA polymerase catalytic subunittarget
DB00811RibavirinCytosolic purine 5'-nucleotidasetarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 1target
DB00811RibavirinGenome polyproteintarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 2target
DB00811RibavirinAdenosine kinaseenzyme
DB00811RibavirinEquilibrative nucleoside transporter 1transporter
DB00811RibavirinSolute carrier family 28 member 3transporter
DrugDrug NamePhaseStatusCount
DB09102Daclatasvir0Completed1
DB09102Daclatasvir0Not Yet Recruiting1
DB06756Glycine betaine0Terminated1
DB09027Ledipasvir0Completed1
DB00008Peginterferon alfa-2a0Terminated1
DB00811Ribavirin0Terminated1
DB08934Sofosbuvir0Completed1
DB08934Sofosbuvir0Not Yet Recruiting1
DB01072Atazanavir1Completed1
DB06576Baminercept1Unknown Status1
DB05665Boceprevir1Terminated1
DB08873Boceprevir1Terminated1
DB00201Caffeine1Completed1
DB08936Chlorcyclizine1Completed1
DB00091Ciclosporin1Completed1
DB09102Daclatasvir1Completed1
DB11779Danoprevir1Completed2
DB05021EMZ7021Completed1
DB11574Elbasvir1Completed1
DB00977Ethinylestradiol1Completed2
DB00973Ezetimibe1Recruiting1
DB11808Faldaprevir1Completed1
DB11878Filibuvir1Completed1
DB12785Furaprevir1Completed1
DB11575Grazoprevir1Completed1
DB11575Grazoprevir1Withdrawn1
DB00367Levonorgestrel1Completed1
DB12045Mericitabine1Completed1
DB00683Midazolam1Completed1
DB14375Milk thistle1Completed1
DB12851Miravirsen1Completed1
DB00957Norgestimate1Completed1
DB13041Odalasvir1Completed2
DB00338Omeprazole1Completed1
DB00008Peginterferon alfa-2a1Completed3
DB00022Peginterferon alfa-2b1Completed2
DB00022Peginterferon alfa-2b1Withdrawn1
DB00811Ribavirin1Completed8
DB00811Ribavirin1Withdrawn1
DB00503Ritonavir1Completed5
DB11713Ruzasvir1Completed1
DB12451SCY-6351Completed1
DB12660Samatasvir1Completed3
DB06290Simeprevir1Completed3
DB11822TMC-6470551Completed1
DB00864Tacrolimus1Completed1
DB00675Tamoxifen1Completed1
DB05521Telaprevir1Completed5
DB00300Tenofovir disoproxil1Completed1
DB01124Tolbutamide1Completed1
DB00577Valaciclovir1Completed1
DB11929Vaniprevir1Completed1
DB11929Vaniprevir1Terminated1
DB11613Velpatasvir1Completed1
DB11586Asunaprevir1 / 2Completed1
DB12885CF-1021 / 2Completed1
DB05916CT-0111 / 2Terminated1
DB09102Daclatasvir1 / 2Completed1
DB00105Interferon alfa-2b1 / 2Completed1
DB01167Itraconazole1 / 2Completed1
DB12232KRN-70001 / 2Completed1
DB00008Peginterferon alfa-2a1 / 2Completed1
DB00008Peginterferon alfa-2a1 / 2Unknown Status1
DB00811Ribavirin1 / 2Unknown Status1
DB04900Thymalfasin1 / 2Completed1
DB05396Albinterferon Alfa-2B2Completed2
DB12139Alisporivir2Completed2
DB11586Asunaprevir2Completed4
DB11586Asunaprevir2Recruiting1
DB05904BLX-8832Completed1
DB12283Balapiravir2Completed1
DB05665Boceprevir2Completed2
DB08873Boceprevir2Completed4
DB12372CTS-10272Completed1
DB06580Celgosivir2Completed3
DB06580Celgosivir2Unknown Status1
DB00091Ciclosporin2Completed1
DB05868Ciluprevir2Completed1
DB13130Ciluprevir2Completed1
DB01394Colchicine2Terminated1
DB09102Daclatasvir2Completed9
DB11779Danoprevir2Completed9
DB11779Danoprevir2Withdrawn1
DB09183Dasabuvir2Active Not Recruiting1
DB09183Dasabuvir2Completed10
DB06700Desvenlafaxine2Completed2
DB06210Eltrombopag2Completed1
DB05408Emricasan2Completed1
DB00153Ergocalciferol2Completed1
DB01175Escitalopram2Completed1
DB00973Ezetimibe2Recruiting1
DB11808Faldaprevir2Completed5
DB01095Fluvastatin2Completed1
DB12785Furaprevir2Completed1
DB12876GS-92562Completed1
DB13879Glecaprevir2Completed3
DB05475Golotimod2Completed1
DB11575Grazoprevir2Completed2
DB11575Grazoprevir2Terminated1
DB05776IC412Completed2
DB05803ISIS 148032Completed1
DB00034Interferon Alfa-2a, Recombinant2Completed2
DB05600Interferon alfa-2b2Completed1
DB09027Ledipasvir2Completed10
DB09027Ledipasvir2Recruiting1
DB09027Ledipasvir2Terminated1
DB11954Lomibuvir2Terminated1
DB12045Mericitabine2Completed9
DB12045Mericitabine2Withdrawn1
DB14375Milk thistle2Completed1
DB12851Miravirsen2Unknown Status1
DB05063Mitoquinone2Completed1
DB14760Narlaprevir2Completed1
DB00507Nitazoxanide2Completed4
DB13041Odalasvir2Completed4
DB09296Ombitasvir2Active Not Recruiting1
DB09296Ombitasvir2Completed11
DB09296Ombitasvir2Recruiting1
DB11133Omega-3 fatty acids2Unknown Status1
DB12896PSI-3529382Completed1
DB09297Paritaprevir2Active Not Recruiting1
DB09297Paritaprevir2Completed14
DB09297Paritaprevir2Recruiting1
DB00008Peginterferon alfa-2a2Completed44
DB00008Peginterferon alfa-2a2Recruiting1
DB00008Peginterferon alfa-2a2Unknown Status2
DB00008Peginterferon alfa-2a2Withdrawn1
DB00022Peginterferon alfa-2b2Completed10
DB00022Peginterferon alfa-2b2Terminated2
DB13878Pibrentasvir2Completed4
DB01132Pioglitazone2Completed1
DB04951Pirfenidone2Completed1
DB09287Polyethylene glycol2Completed4
DB09287Polyethylene glycol2Terminated1
DB11077Polyethylene glycol 4002Completed4
DB11077Polyethylene glycol 4002Terminated1
DB00457Prazosin2Unknown Status1
DB00635Prednisone2Completed1
DB12065Radalbuvir2Completed2
DB00811Ribavirin2Active Not Recruiting1
DB00811Ribavirin2Completed103
DB00811Ribavirin2Recruiting1
DB00811Ribavirin2Terminated4
DB00811Ribavirin2Unknown Status3
DB00811Ribavirin2Withdrawn1
DB00503Ritonavir2Active Not Recruiting1
DB00503Ritonavir2Completed21
DB00503Ritonavir2Recruiting1
DB00503Ritonavir2Withdrawn1
DB11713Ruzasvir2Terminated1
DB12051Setrobuvir2Completed2
DB09298Silibinin2Completed1
DB06290Simeprevir2Completed12
DB06290Simeprevir2Recruiting1
DB09153Sodium chloride2Unknown Status1
DB08934Sofosbuvir2Active Not Recruiting1
DB08934Sofosbuvir2Completed19
DB08934Sofosbuvir2Recruiting1
DB12069Sovaprevir2Completed1
DB11822TMC-6470552Completed1
DB00864Tacrolimus2Completed1
DB06408Taribavirin2Completed1
DB06408Taribavirin2Terminated1
DB11852Tegobuvir2Completed4
DB05521Telaprevir2Completed8
DB05521Telaprevir2Terminated1
DB05521Telaprevir2Unknown Status1
DB04900Thymalfasin2Completed2
DB00577Valaciclovir2Completed1
DB11929Vaniprevir2Completed1
DB12037Vedroprevir2Completed5
DB12037Vedroprevir2Terminated1
DB11613Velpatasvir2Active Not Recruiting1
DB11613Velpatasvir2Completed5
DB11094Vitamin D2Completed1
DB12026Voxilaprevir2Completed2
DB05665Boceprevir2 / 3Terminated1
DB08873Boceprevir2 / 3Terminated1
DB09102Daclatasvir2 / 3Completed2
DB09102Daclatasvir2 / 3Recruiting1
DB09183Dasabuvir2 / 3Completed1
DB09183Dasabuvir2 / 3Recruiting1
DB11574Elbasvir2 / 3Completed1
DB00442Entecavir2 / 3Recruiting1
DB13879Glecaprevir2 / 3Completed1
DB11575Grazoprevir2 / 3Completed1
DB00105Interferon alfa-2b2 / 3Completed1
DB09027Ledipasvir2 / 3Recruiting1
DB00331Metformin2 / 3Unknown Status1
DB14760Narlaprevir2 / 3Terminated1
DB00507Nitazoxanide2 / 3Completed2
DB09296Ombitasvir2 / 3Completed1
DB09296Ombitasvir2 / 3Recruiting1
DB09297Paritaprevir2 / 3Completed1
DB09297Paritaprevir2 / 3Recruiting1
DB00008Peginterferon alfa-2a2 / 3Completed3
DB00008Peginterferon alfa-2a2 / 3Unknown Status2
DB00022Peginterferon alfa-2b2 / 3Completed1
DB00022Peginterferon alfa-2b2 / 3Terminated1
DB00022Peginterferon alfa-2b2 / 3Withdrawn1
DB13878Pibrentasvir2 / 3Completed1
DB00811Ribavirin2 / 3Active Not Recruiting1
DB00811Ribavirin2 / 3Completed5
DB00811Ribavirin2 / 3Terminated1
DB00811Ribavirin2 / 3Unknown Status1
DB00811Ribavirin2 / 3Withdrawn1
DB00503Ritonavir2 / 3Completed1
DB00503Ritonavir2 / 3Recruiting1
DB09298Silibinin2 / 3Withdrawn1
DB00641Simvastatin2 / 3Completed1
DB08934Sofosbuvir2 / 3Active Not Recruiting1
DB08934Sofosbuvir2 / 3Completed2
DB08934Sofosbuvir2 / 3Recruiting1
DB00300Tenofovir disoproxil2 / 3Recruiting1
DB09145Water2 / 3Completed1
DB12139Alisporivir3Completed1
DB00915Amantadine3Completed2
DB00915Amantadine3Terminated1
DB11586Asunaprevir3Completed1
DB05665Boceprevir3Completed5
DB08873Boceprevir3Completed8
DB05665Boceprevir3Withdrawn2
DB08873Boceprevir3Withdrawn2
DB00091Ciclosporin3Terminated1
DB09065Cobicistat3Active Not Recruiting1
DB09102Daclatasvir3Completed4
DB09102Daclatasvir3Not Yet Recruiting1
DB09102Daclatasvir3Recruiting1
DB11779Danoprevir3Completed1
DB09183Dasabuvir3Completed16
DB09183Dasabuvir3Terminated1
DB11574Elbasvir3Completed2
DB11574Elbasvir3Not Yet Recruiting1
DB06210Eltrombopag3Completed2
DB09101Elvitegravir3Active Not Recruiting1
DB00879Emtricitabine3Active Not Recruiting1
DB00153Ergocalciferol3Terminated1
DB00016Erythropoietin3Completed2
DB11808Faldaprevir3Completed2
DB13879Glecaprevir3Active Not Recruiting1
DB13879Glecaprevir3Completed7
DB11575Grazoprevir3Completed2
DB11575Grazoprevir3Not Yet Recruiting1
DB00069Interferon alfacon-13Completed1
DB01029Irbesartan3Completed1
DB09027Ledipasvir3Active Not Recruiting1
DB09027Ledipasvir3Completed2
DB09027Ledipasvir3Recruiting1
DB00331Metformin3Terminated1
DB09296Ombitasvir3Completed17
DB09296Ombitasvir3Terminated1
DB09297Paritaprevir3Completed17
DB09297Paritaprevir3Terminated1
DB00715Paroxetine3Completed1
DB00008Peginterferon alfa-2a3Completed30
DB00008Peginterferon alfa-2a3Terminated3
DB00008Peginterferon alfa-2a3Unknown Status1
DB00008Peginterferon alfa-2a3Withdrawn2
DB00022Peginterferon alfa-2b3Completed23
DB00022Peginterferon alfa-2b3Terminated4
DB00022Peginterferon alfa-2b3Withdrawn3
DB13878Pibrentasvir3Active Not Recruiting1
DB13878Pibrentasvir3Completed6
DB01132Pioglitazone3Terminated1
DB09287Polyethylene glycol3Completed5
DB09287Polyethylene glycol3Terminated1
DB11077Polyethylene glycol 4003Completed5
DB11077Polyethylene glycol 4003Terminated1
DB00811Ribavirin3Completed82
DB00811Ribavirin3Recruiting1
DB00811Ribavirin3Terminated10
DB00811Ribavirin3Unknown Status2
DB00811Ribavirin3Withdrawn7
DB00503Ritonavir3Completed18
DB00503Ritonavir3Terminated1
DB06290Simeprevir3Completed7
DB06290Simeprevir3Recruiting1
DB08934Sofosbuvir3Active Not Recruiting1
DB08934Sofosbuvir3Completed9
DB08934Sofosbuvir3Not Yet Recruiting1
DB08934Sofosbuvir3Recruiting2
DB06408Taribavirin3Completed2
DB05521Telaprevir3Completed12
DB05521Telaprevir3Terminated1
DB05521Telaprevir3Withdrawn1
DB09299Tenofovir alafenamide3Active Not Recruiting1
DB04900Thymalfasin3Completed2
DB11251Tocopherol3Terminated1
DB01586Ursodeoxycholic acid3Completed1
DB11929Vaniprevir3Completed3
DB11613Velpatasvir3Recruiting1
DB11094Vitamin D3Terminated1
DB00284Acarbose4Unknown Status1
DB00126Ascorbic acid4Completed1
DB11586Asunaprevir4Recruiting1
DB11586Asunaprevir4Withdrawn1
DB12225Beclabuvir4Withdrawn1
DB08873Boceprevir4Completed2
DB08873Boceprevir4Unknown Status1
DB04887Brecanavir4Withdrawn1
DB00921Buprenorphine4Terminated1
DB09065Cobicistat4Recruiting1
DB09102Daclatasvir4Completed3
DB09102Daclatasvir4Withdrawn1
DB09183Dasabuvir4Active Not Recruiting2
DB09183Dasabuvir4Recruiting1
DB00625Efavirenz4Active Not Recruiting1
DB11574Elbasvir4Active Not Recruiting1
DB11574Elbasvir4Completed1
DB11574Elbasvir4Recruiting2
DB09101Elvitegravir4Recruiting1
DB00879Emtricitabine4Recruiting1
DB00153Ergocalciferol4Terminated1
DB00016Erythropoietin4Completed1
DB00016Erythropoietin4Unknown Status1
DB06414Etravirine4Withdrawn1
DB13879Glecaprevir4Recruiting1
DB11575Grazoprevir4Active Not Recruiting1
DB11575Grazoprevir4Completed1
DB11575Grazoprevir4Recruiting2
DB00034Interferon Alfa-2a, Recombinant4Completed1
DB09027Ledipasvir4Active Not Recruiting1
DB09027Ledipasvir4Completed2
DB09027Ledipasvir4Recruiting2
DB00678Losartan4Completed1
DB04835Maraviroc4Withdrawn1
DB00331Metformin4Completed2
DB00331Metformin4Unknown Status2
DB00333Methadone4Terminated1
DB00507Nitazoxanide4Completed1
DB00507Nitazoxanide4Unknown Status1
DB09296Ombitasvir4Active Not Recruiting2
DB09297Paritaprevir4Active Not Recruiting2
DB00008Peginterferon alfa-2a4Completed43
DB00008Peginterferon alfa-2a4Terminated2
DB00008Peginterferon alfa-2a4Unknown Status5
DB00022Peginterferon alfa-2b4Completed4
DB00022Peginterferon alfa-2b4Terminated4
DB00022Peginterferon alfa-2b4Unknown Status1
DB01132Pioglitazone4Completed2
DB01132Pioglitazone4Unknown Status1
DB09287Polyethylene glycol4Completed1
DB11077Polyethylene glycol 4004Completed1
DB06817Raltegravir4Active Not Recruiting1
DB00811Ribavirin4Completed52
DB00811Ribavirin4Terminated8
DB00811Ribavirin4Unknown Status4
DB00503Ritonavir4Active Not Recruiting2
DB00412Rosiglitazone4Terminated1
DB06290Simeprevir4Completed2
DB06290Simeprevir4Withdrawn1
DB08934Sofosbuvir4Active Not Recruiting1
DB08934Sofosbuvir4Completed7
DB08934Sofosbuvir4Enrolling by Invitation1
DB08934Sofosbuvir4Not Yet Recruiting1
DB08934Sofosbuvir4Recruiting6
DB08934Sofosbuvir4Withdrawn1
DB09299Tenofovir alafenamide4Recruiting1
DB11613Velpatasvir4Enrolling by Invitation1
DB11613Velpatasvir4Not Yet Recruiting1
DB11613Velpatasvir4Recruiting4
DB11094Vitamin D4Terminated1
DB12026Voxilaprevir4Not Yet Recruiting1
DB12139AlisporivirNot AvailableCompleted1
DB11586AsunaprevirNot AvailableNot Yet Recruiting1
DB08873BoceprevirNot AvailableCompleted2
DB08873BoceprevirNot AvailableRecruiting2
DB08873BoceprevirNot AvailableTerminated1
DB00921BuprenorphineNot AvailableCompleted1
DB09102DaclatasvirNot AvailableCompleted1
DB09102DaclatasvirNot AvailableNo Longer Available2
DB09102DaclatasvirNot AvailableNot Yet Recruiting1
DB09102DaclatasvirNot AvailableRecruiting3
DB09183DasabuvirNot AvailableCompleted4
DB09183DasabuvirNot AvailableRecruiting2
DB11574ElbasvirNot AvailableRecruiting2
DB00153ErgocalciferolNot AvailableUnknown Status1
DB13879GlecaprevirNot AvailableNot Yet Recruiting1
DB06756Glycine betaineNot AvailableWithdrawn1
DB05475GolotimodNot AvailableCompleted1
DB11575GrazoprevirNot AvailableRecruiting2
DB00105Interferon alfa-2bNot AvailableTerminated1
DB09027LedipasvirNot AvailableCompleted1
DB09027LedipasvirNot AvailableRecruiting3
DB09296OmbitasvirNot AvailableCompleted4
DB09296OmbitasvirNot AvailableRecruiting1
DB09297ParitaprevirNot AvailableCompleted4
DB09297ParitaprevirNot AvailableRecruiting1
DB00008Peginterferon alfa-2aNot AvailableCompleted18
DB00008Peginterferon alfa-2aNot AvailableNo Longer Available1
DB00008Peginterferon alfa-2aNot AvailableTerminated2
DB00008Peginterferon alfa-2aNot AvailableWithdrawn1
DB00022Peginterferon alfa-2bNot AvailableCompleted28
DB00022Peginterferon alfa-2bNot AvailableTerminated2
DB00022Peginterferon alfa-2bNot AvailableWithdrawn1
DB13878PibrentasvirNot AvailableNot Yet Recruiting1
DB01132PioglitazoneNot AvailableCompleted1
DB09287Polyethylene glycolNot AvailableCompleted1
DB09287Polyethylene glycolNot AvailableUnknown Status1
DB11077Polyethylene glycol 400Not AvailableCompleted1
DB11077Polyethylene glycol 400Not AvailableUnknown Status1
DB00811RibavirinNot AvailableCompleted49
DB00811RibavirinNot AvailableNo Longer Available2
DB00811RibavirinNot AvailableRecruiting1
DB00811RibavirinNot AvailableTerminated8
DB00811RibavirinNot AvailableUnknown Status4
DB00811RibavirinNot AvailableWithdrawn2
DB01220RifaximinNot AvailableActive Not Recruiting1
DB00503RitonavirNot AvailableCompleted4
DB06290SimeprevirNot AvailableCompleted1
DB06290SimeprevirNot AvailableRecruiting2
DB06290SimeprevirNot AvailableTerminated1
DB08934SofosbuvirNot AvailableCompleted2
DB08934SofosbuvirNot AvailableNo Longer Available2
DB08934SofosbuvirNot AvailableRecruiting3
DB05521TelaprevirNot AvailableCompleted1
DB05521TelaprevirNot AvailableRecruiting2
DB11613VelpatasvirNot AvailableRecruiting2
DB11094Vitamin DNot AvailableUnknown Status1